Lymphoma, Non-Hodgkin's, Adult
Conditions
Brief summary
The purpose of this research is to help researchers find out if SP-3164 is safe and if it may be of benefit in the treatment of patients with Non-Hodgkin's lymphoma that has progressed after prior treatment, or that never responded to previous treatment.
Detailed description
SALA-003-NHL is a phase 1 open-label, multicenter, first-in-human study of SP-3164 in patients with R/R B-cell NHL that will be conducted in two parts. Part 1 is a dose escalation using a sequential accelerated titration design for the first two dose levels followed by a 3+3 dose escalation design to assess the safety and tolerability of SP-3164 in patients with R/R B-cell NHL. Upon completion of the dose escalation design and review of all available safety, tolerability, PK, PD, and preliminary efficacy data the Safety Review Committee (SRC) will recommend two dose levels for the randomized dose selection optimization (Part 2). The dose selection optimization will randomize 1:1 approximately 30 patients with R/R DLBCL to the two selected dose levels (15 new patients per dose level) to determine the recommended phase 2 dose (RP2D) and further characterize safety, tolerability, PK, PD, and preliminary efficacy data of SP-3164. SP-3164 will be administered orally once daily under fasting conditions on 7 consecutive on-treatment days followed by 7 consecutive off-treatment days. One treatment cycle will be defined as 28 days.
Interventions
DRUGSP-3164
SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
Sponsors
Salarius Pharmaceuticals, LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This study is a phase 1, open-label, multicenter, dose escalation (part 1) and dose selection optimization (part 2) study of SP-3164 in patients with R/R B-cell NHL.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Diagnosis (WHO 2016 criteria) of R/R B-cell NHL in dose escalation (part 1) and limited to R/R DLBCL in dose selection optimization (part 2) confirmed by biopsy and immunophenotyping Dose escalation: at time of enrollment, R/R B-cell NHL patients per WHO 2016 criteria including DLBCL (including low grade transformed lymphoma), mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma and must: * require treatment in the opinion of the Investigator * received at least 2 lines of systemic therapy for B-cell NHL Dose selection optimization: at time of enrollment, R/R DLBCL (including low grade transformed lymphoma) patients must have received 2 or 3 lines of systemic therapy for DLBCL o Prior immunomodulatory imide drug (IMiD) therapy is allowed (e.g., lenalidomide) Measurable disease per the 2017 International Working Group Consensus Response Evaluation Criteria for Lymphoma Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 Existing archival tumor tissue (fresh frozen paraffin embedded \[FFPE\], 5 unstained slides) not older than 2 years from Cycle 1 Day 1 or willingness to provide fresh tumor biopsy during screening Normal organ and marrow function, defined by specific laboratory parameters Ability to take orally administered medication Washout period prior to Cycle 1 Day 1 of SP-3164: at least 21 days or 5 half-lives (whichever is shorter) from prior systemic anticancer treatment, including chemotherapy, biologic therapy, small molecule inhibitors, monoclonal antibodies, and any investigational agents; at least 14 days from palliative radiotherapy if ≤ 10 fractions or total dose ≤ 30 gray (Gy) or at least 28 days from radiotherapy if total dose \> 30 Gy; at least 21 days from major surgery Life expectancy of at least 3 months
Exclusion criteria
Patients with chronic lymphocytic leukemia, high grade B-cell lymphoma, or Richter's syndrome Patients who have not recovered to Grade 1 toxicity or baseline due to any previous anticancer therapy according to the NCI CTCAE v5.0, excluding Grade 2 alopecia. Lymphopenia ≤ Grade 2 is allowed Patients with primary central nervous system (CNS) lymphoma or active CNS or meningeal lymphomatous involvement Persistent diarrhea or malabsorption of ≥ Grade 2 despite medical management Impaired cardiac function or clinically significant cardiac disease, including symptomatic congestive heart failure, left ventricular ejection fraction (LVEF) \< 50%, unstable angina pectoris or cardiac arrhythmias, baseline QTc (Fridericia) \> 450 milliseconds, long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, myocardial infarct within 6 months of study enrollment, clinically significant pericardial disease Solid organ transplant recipient Allogeneic stem cell transplantation (SCT) recipient Autologous SCT recipient \<100 days from Cycle 1 Day 1 or otherwise not fully recovered from SCT-related toxicity Completion of CAR-T therapy \< 90 days from Cycle 1 Day 1 Systemic immunosuppressants and chronic systemic corticosteroids (at doses ≥ 10 mg/day of prednisone or equivalent) are prohibited Malignant disease, other than that being treated in this study. Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) who have undergone potentially curative therapy are not excluded. Other exceptions include malignancies that were treated curatively and have not recurred within 3 years prior to Cycle 1 Day 1 and any malignancy considered indolent and that has never required therapy Other concurrent severe or uncontrolled concomitant medical conditions that might cause unacceptable safety risks or compromise compliance with the protocol Pregnant and breastfeeding women Known history of HIV-positivity; known hepatitis B or hepatitis C virus infection Men and women of child-bearing potential unwilling to use adequate contraception according to study protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Escalation: Characterize the Safety of SP-3164 | 4 months | Dose Escalation (Part 1) • To characterize the safety, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of SP-3164 |
| Dose Escalation: Assess Dose Limiting Toxicities of SP-3164 | 6 months | Dose Escalation (Part 1) • To characterize the safety, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of SP-3164 |
| Dose Escalation: Assess the Maximum Tolerated Dose of SP-3164 | 6 months | Dose Escalation (Part 1) • To characterize the safety, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of SP-3164 |
| Dose Optimization: Further characterize the safety of the 2 selected doses of SP-3164 from Part 1 (dose escalation) | 6 months | Dose Selection Optimization (Part 2) • To further characterize the safety of the two selected doses of SP-3164 from part 1 and determine the recommended phase 2 dose (RP2D) of SP-3164 for future studies |
| Dose Optimization: Determine the recommended phase 2 dose of SP-3164 for future studies | 6 months | • To further characterize the safety of the two selected doses of SP-3164 from part 1 and determine the recommended phase 2 dose (RP2D) of SP-3164 for future studies |
Contacts
Primary ContactRebecca Griffith-Eskew
Outcome results
None listed